Cantor Fitzgerald Comments on GH Research FY2024 Earnings

GH Research PLC (NASDAQ:GHRS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for GH Research in a report issued on Thursday, February 13th. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings of ($0.79) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $14.00 price objective on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share. Cantor Fitzgerald also issued estimates for GH Research's FY2025 earnings at ($0.80) EPS.

A number of other research analysts also recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Canaccord Genuity Group dropped their price target on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th.

GH Research Stock Performance

Shares of GHRS traded down $0.01 during trading hours on Monday, hitting $13.99. The stock had a trading volume of 266,909 shares, compared to its average volume of 696,861. The firm has a market capitalization of $727.64 million, a price-to-earnings ratio of -17.70 and a beta of 0.93. The firm has a 50-day moving average price of $9.94 and a 200 day moving average price of $9.14. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Woodline Partners LP increased its position in GH Research by 112.0% during the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company's stock worth $553,000 after purchasing an additional 41,711 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of GH Research during the 4th quarter worth approximately $117,000. Millennium Management LLC purchased a new stake in shares of GH Research during the 4th quarter valued at approximately $145,000. BNP Paribas Financial Markets acquired a new position in GH Research in the fourth quarter valued at approximately $44,000. Finally, AdvisorShares Investments LLC grew its position in GH Research by 15.4% in the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after acquiring an additional 4,806 shares during the period. Institutional investors and hedge funds own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).